We found for
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

Payment Models for Multi-Indication Therapies

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

The Lower Drug Costs Now Act and Pharmaceutical Innovation
